India Exchange Filings

Alivus Acquisition Update: IQGEN-X Pharma

Alivus Life Sciences Ltd acquires 65.01% of IQGEN-X Pharma, making it a subsidiary

  • Acquired 7,36,096 equity shares under the share purchase agreement.
  • IQGEN-X became a subsidiary effective November 11, 2026; the remaining share capital is to be acquired in due course.
  • The agreement, announced August 18, 2026, covered a proposed 76% stake.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.